# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123248
Filing Date
2024-11-07
Accepted
2024-11-07 16:02:05
Documents
75
Period of Report
2024-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | aldx-20240930.htm iXBRL | 10-Q | 1888933
2 | EX-10.3 | aldx-ex10_3.htm | EX-10.3 | 187837
3 | EX-10.4 | aldx-ex10_4.htm | EX-10.4 | 80105
4 | EX-31.1 | aldx-ex31_1.htm | EX-31.1 | 16323
5 | EX-31.2 | aldx-ex31_2.htm | EX-31.2 | 16569
6 | EX-32.1 | aldx-ex32_1.htm | EX-32.1 | 11793
7 | GRAPHIC | img130890548_0.jpg | GRAPHIC | 79815
| Complete submission text file | 0000950170-24-123248.txt |  | 7489439

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | aldx-20240930.xsd | EX-101.SCH | 1000308
77 | EXTRACTED XBRL INSTANCE DOCUMENT | aldx-20240930_htm.xml | XML | 1002524

Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 241435402
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)